The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System

Value in Health Regional Issues

Volumn 1, Issue 2, 2012, Pages 165-171

  Guillermo Ariza, Juan ^a   Thuresson, Per Olof ^b   Machnicki, Gerardo ^c   Mungapen, Laura ^b   Kraemer, Matthias ^d   Asukai, Yumi ^b   Fernando Giraldo, Luis ^e  

^a Novartis   (Colombia)

^b IQVIA   (United States)

^c Novartis Latin America and Canada   (Argentina)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSIDAD DE LA SABANA   (Colombia)

Author keywords

Colombia; COPD; Cost effectiveness; Indacaterol

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; INDACATEROL; PLACEBO; TIOTROPIUM BROMIDE;

ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLOMBIA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH CARE SYSTEM; HIDDEN MARKOV MODEL; HUMAN; LIFE TABLE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SIMULATION; TREATMENT RESPONSE;

EID: 84870904837     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2012.09.003     Document Type: Article

References (30)

1. Caballero A., Torres-Duque C.A., Jaramillo C., et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest 2008, 133:343-349.
2. Departamento Administrativo Nacional de Estadística. Proyecciones nacionales y departamentales de población 2005-2020. [Accessed August 28, 2012]. http://www.dane.gov.co/7E6820E3-5620-4692-8068-414B56D829F2/FinalDownload/DownloadId-D83E1F8F60C9B32826937968C9D17ECE/7E6820E3-5620-4692-8068-414B56D829F2/files/investigaciones/poblacion/proyepobla06_20/8Tablasvida1985_2020.pdf.
3. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org/.
4. Acosta N, Peñaloza RE, Rodríguez-García J. Carga de Enfermedad Colombia 2005: Resultados Alcanzados. Cendex 2008; Available from: http://www.cendex.org.co/GPES/informes/PresentacionCarga_Informe.pdf.
5. Price D., Gray A., Gale R., et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med 2011, 105:1635-1647.
6. Pérez N., Murillo R., Pinzón C., Hernández G. Costos de la atención médica del cáncer de pulmón, la EPOC y el IAM atribuibles al consumo de tabaco en Colombia (proyecto multicéntrico de la OPS)^ies. Rev Colomb Cancerol 2007, 11:241-249.
7. Jochmann A, Neubauer F, Miedinger D, Schafroth S, Tamm M, Leuppi JD. General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly. 2010.
8. Pauwels R.A., Buist A.S., Ma P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001, 46:798-825.
9. Donohue J.F., Fogarty C., Lotvall J., et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010, 182:155-162.
10. Falaschetti E., Laiho J., Primatesta P., Purdon S. Prediction equations for normal and low lung function from the Health Survey for England. Eur Respir J 2004, 23:456-463.
11. 1 in relation to incident chronic obstructive pulmonary disease in a cohort with respiratory symptoms. COPD 2007, 4:5-13.
12. Cope S., Capkun-Niggli G., Gale R., et al. Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis. Int J Chron Obstruct Pulmon Dis 2011, 6:329-344.
13. Caldwell D.M., Ades A.E., Higgins J.P. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331:897-900.
14. Hoogendoorn M., Feenstra T.L., Hoogenveen R.T., et al. Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis 2010, 5:435-444.
15. Rutten-van Molken M.P., Oostenbrink J.B., Miravitlles M., Monz B.U. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007, 8:123-135.
16. Pachón A., Perea E., Celis C., et al. Proyecciones de Poblacion 2005-2020 2007, 8:1-244. Available from http://www.dane.gov.co/files/investigaciones/poblacion/proyepobla06_20/8Tablasvida1985_2020.pdf.
17. Kind P., Dolan P., Gudex C., Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998, 316:736-741.
18. Stahl E., Wadbo M., Bengtsson T., et al. Health-related quality of life, symptoms, exercise capacity and lung function during treatment for moderate to severe COPD. J Outcomes Res 2001, 5:11-24.
19. Rutten-van Molken M.P., Hoogendoorn M., Lamers L.M. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics 2009, 27:465-477.
20. Ministerio de protección social de la republica de Colombia. Resolución de precios 4316 del 2011. [Accessed August 28, 2012]. http://www.Acin.org/acin/new/Portals/0/resolucion_4316_de_2011.pdf.
21. Sistema Integral de Información de la Protección Social, SISPROSistema de Información de Precios de Medicamentos, SISMED. 2008. Disponible en: http://www2.sispro.gov.co/Paginas/Publicaciones.aspx.
22. Departamento de Admiistración Nacional de Estadística DANE. Republica de Colombia. Colombia, Indice de Precios al Consumidor (IPC). [Accessed August 28, 2012]. http://www.dane.gov.co/files/investigaciones/ipc/abr12/IPC_Variacion.xls.
23. Banco de la Republica Colombia. Exchange rates. [Accessed August 28, 2012]. http://www.Banrep.gov.co/series-estadisticas/see_ts_trm.htm#cotizaci.
24. Jochmann A., Neubauer F., Miedinger D., et al. General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly 2010 April 21 AU: Provide page range fro reference 24.
25. Scanlon P.D., Connett J.E., Wise R.A., et al. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 2004, 170:1302-1309.
26. Loke Y.K., Cavallazzi R., Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011, 66:699-708.
27. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010, 123:1001-1006.
28. Spencer S., Karner C., Cates C.J., Evans D.J. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011, CD007033.
29. Brassard P., Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011, 183:675-678.
30. Shu C.C., Wu H.D., Yu M.C., et al. Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine (Baltimore) 2010, 89:53-61.